G1 Therapeutics, Inc. (GTHX)

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics for cancer treatment. Their lead product, COSELA, helps reduce chemotherapy-induced myelosuppression in small cell lung cancer patients.

46/100 AI Score MCap $377.75M Vol 1.10M

Company Overview

CEOJohn E. Bailey Jr.
Employees100
HeadquartersResearch Triangle Park, NC, US
IPO Year2017

G1 Therapeutics is pioneering innovative cancer therapies, highlighted by COSELA, a breakthrough treatment reducing chemotherapy side effects, and a robust pipeline targeting significant unmet needs in oncology, positioning the company for substantial growth in the biopharmaceutical sector with a $0.38B market cap.

Investment Thesis

G1 Therapeutics presents a compelling investment opportunity due to its innovative approach to cancer treatment and a promising pipeline of clinical-stage assets. The company's approved product, COSELA, addresses a critical need in chemotherapy-induced myelosuppression, demonstrating significant clinical value. The ongoing Phase III trials for trilaciclib in colorectal and triple-negative breast cancer represent substantial growth catalysts, with potential market expansion upon positive results. Furthermore, the development of lerociclib and rintodestrant offers additional avenues for growth in various oncology indications. With a gross margin of 91.3%, G1 Therapeutics has strong potential for profitability as its pipeline matures. The current market capitalization of $0.38 billion may undervalue the company's long-term potential, especially considering the potential for significant revenue generation from its diverse pipeline and strategic partnerships. Positive clinical trial outcomes and successful commercialization efforts could drive significant shareholder value in the coming years.

Key Highlights

  • COSELA is approved to decrease chemotherapy-induced myelosuppression in adult patients with extensive stage small cell lung cancer.
  • Gross Margin of 91.3% indicates strong potential for profitability as revenue scales.
  • Market Cap of $0.38B may present an undervaluation relative to pipeline potential.
  • Developing trilaciclib in Phase III clinical trials for first line colorectal cancer and triple negative breast cancer.
  • Developing rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer.

Competitors

Strengths

  • Approved product (COSELA) with established clinical benefit.
  • Diverse pipeline of clinical-stage programs.
  • Strategic partnerships and licensing agreements.
  • Strong gross margin (91.3%).

Weaknesses

  • Negative profit margin (-58.1%).
  • Reliance on successful clinical trial outcomes.
  • Competition from established pharmaceutical companies.
  • Limited commercial infrastructure.

Catalysts

  • Upcoming: Results from Phase III clinical trial of trilaciclib in first-line colorectal cancer.
  • Upcoming: Results from Phase III clinical trial of trilaciclib in triple-negative breast cancer.
  • Ongoing: Development and advancement of lerociclib in multiple oncology indications.
  • Ongoing: Commercialization efforts for COSELA to expand market reach.
  • Ongoing: Strategic partnerships and licensing agreements to expand pipeline and market access.

Risks

  • Potential: Clinical trial failures for pipeline programs.
  • Potential: Regulatory delays or non-approval of pipeline products.
  • Ongoing: Competition from established pharmaceutical companies and other cancer therapies.
  • Ongoing: Pricing pressures and reimbursement challenges for COSELA and future products.
  • Potential: Dependence on strategic partners for successful commercialization.

Growth Opportunities

  • Expanding the Label for COSELA: G1 Therapeutics has the opportunity to expand the label for COSELA to include other chemotherapy regimens and cancer types. This could significantly increase the addressable market for COSELA, driving revenue growth. The market for myelosuppression therapies is estimated to reach billions of dollars, with ongoing research and development efforts focused on improving patient outcomes. Timeline: Ongoing clinical trials and regulatory submissions.
  • Advancing Trilaciclib in Colorectal Cancer: The Phase III clinical trial for trilaciclib in first-line colorectal cancer represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, addressing a substantial unmet need in colorectal cancer treatment. The colorectal cancer market is projected to grow significantly in the coming years, driven by increasing incidence rates and advancements in treatment options. Timeline: Phase III trial results expected in the near term.
  • Developing Lerociclib for Multiple Oncology Indications: The development of lerociclib, an oral CDK4/6 inhibitor, for multiple oncology indications offers a broad growth opportunity. CDK4/6 inhibitors have shown significant efficacy in various cancer types, and lerociclib could capture a share of this growing market. The market for CDK4/6 inhibitors is estimated to be worth billions of dollars, with ongoing research focused on expanding their use in different cancer settings. Timeline: Ongoing clinical trials and development efforts.
  • Commercializing Rintodestrant for Breast Cancer: The Phase IIa clinical trials for rintodestrant in estrogen receptor-positive and HER2-negative breast cancer represent a promising growth opportunity. Rintodestrant, as an oral selective estrogen receptor degrader, could provide a valuable treatment option for patients with breast cancer. The breast cancer market is one of the largest oncology markets, with a continuous need for new and effective therapies. Timeline: Phase IIa trial results expected in the medium term.
  • Strategic Partnerships and Licensing Agreements: G1 Therapeutics can continue to pursue strategic partnerships and licensing agreements to expand the development and commercialization of its pipeline products. These collaborations can provide access to new markets, technologies, and resources, accelerating the company's growth. Strategic partnerships are crucial for biotech companies to leverage external expertise and funding, ultimately enhancing their competitive advantage. Timeline: Ongoing business development efforts.

Opportunities

  • Expanding the label for COSELA.
  • Advancing trilaciclib in colorectal and breast cancer.
  • Developing lerociclib for multiple oncology indications.
  • Commercializing rintodestrant for breast cancer.

Threats

  • Clinical trial failures.
  • Regulatory hurdles.
  • Competition from other cancer therapies.
  • Pricing pressures and reimbursement challenges.

Competitive Advantages

  • Proprietary small molecule therapeutics with patent protection.
  • Clinical data supporting the efficacy and safety of COSELA.
  • Strategic partnerships and licensing agreements.
  • Expertise in cancer drug development and commercialization.

About

G1 Therapeutics, Inc., founded in 2008 and headquartered in Research Triangle Park, North Carolina, is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative small molecule therapeutics for cancer patients. The company's initial focus was on addressing significant unmet needs in cancer treatment by developing therapies that improve patient outcomes and quality of life. Their flagship product, COSELA (trilaciclib), is approved to decrease chemotherapy-induced myelosuppression in adult patients receiving certain chemotherapy regimens for extensive-stage small cell lung cancer. Beyond COSELA, G1 Therapeutics has a diverse pipeline of clinical-stage programs, including trilaciclib in various Phase II and Phase III trials for colorectal cancer, triple-negative breast cancer, and bladder cancer. Additionally, the company is developing lerociclib, an oral CDK4/6 inhibitor, and rintodestrant, an oral selective estrogen receptor degrader, for multiple oncology indications, including breast cancer. G1 Therapeutics has also established strategic partnerships and licensing agreements with companies like EQRx, Genor Biopharma, Nanjing Simcere Dongyuan Pharmaceutical, and ARC Therapeutics to expand the development and commercialization of its pipeline products. With approximately 100 employees, G1 Therapeutics is committed to advancing cancer care through innovative science and strategic collaborations.

What They Do

  • Develops small molecule therapeutics for cancer treatment.
  • Offers COSELA to decrease chemotherapy-induced myelosuppression.
  • Conducts clinical trials for trilaciclib in various cancer types.
  • Develops lerociclib, an oral CDK4/6 inhibitor, for multiple oncology indications.
  • Develops rintodestrant, an oral selective estrogen receptor degrader, for breast cancer.
  • Engages in strategic partnerships and licensing agreements.

Business Model

  • Develops and commercializes proprietary cancer therapies.
  • Generates revenue through product sales of COSELA.
  • Out-licenses certain rights to partners for specific territories and indications.
  • Advances pipeline programs through clinical trials to increase product value.

Industry Context

G1 Therapeutics operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation and high-growth potential. The oncology market is a significant driver within the biotechnology sector, with increasing demand for novel therapies and personalized medicine approaches. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, all vying for market share in various cancer indications. G1 Therapeutics differentiates itself through its focus on developing small molecule therapeutics that address critical unmet needs in cancer treatment, such as reducing chemotherapy-induced side effects. The company's strategic partnerships and licensing agreements further enhance its competitive position, allowing for broader development and commercialization of its pipeline products.

Key Customers

  • Adult patients with extensive stage small cell lung cancer undergoing chemotherapy.
  • Oncologists and healthcare providers who prescribe cancer treatments.
  • Hospitals and cancer centers that administer chemotherapy.
  • Strategic partners and licensees who commercialize products in specific territories.
AI Confidence: 72% Updated: 2/3/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 2024 $17M -$5M $-0.10
Q1 2024 $14M -$10M $-0.20
Q4 2023 $15M -$11M $-0.21
Q3 2023 $12M -$18M $-0.35

Source: Company filings

Chart & Info

Price Chart

G1 Therapeutics, Inc. (GTHX) stock price: $7.16 (+0.00, +0.00%)

Why Bull

  • •GTHX has seen some insider buying recently, which often signals confidence from those who know the company best. It's a positive sign, similar to when insiders loaded up on Tesla before its big 2020 rally.
  • •The community sentiment around GTHX seems to be cautiously optimistic. There's a feeling that the company is undervalued, and positive news could be a catalyst for growth.
  • •There's a growing perception that GTHX's pipeline is promising. The market is starting to recognize the potential of their drugs, which could lead to increased investor interest.
  • •Recent market developments have been favorable for biotech companies in general. This rising tide could lift GTHX along with it, much like how the tech boom benefited many companies during the late 90s.

Why Bear

  • •Despite some insider buying, overall insider activity has been mixed. Some insiders have also sold shares, which could indicate concerns about the company's future performance. It's a bit like the mixed signals seen before the dot-com bubble burst.
  • •Community sentiment, while cautiously optimistic, also reveals concerns about GTHX's cash burn. There's a worry that the company might need to raise more capital, potentially diluting existing shareholders.
  • •The market perception of GTHX is still largely dependent on clinical trial results. Any setbacks could significantly impact the stock price, similar to how negative news affected many financial institutions during the 2008 crisis.
  • •Recent market volatility has created a risk-off environment. Investors are becoming more cautious, which could hurt smaller biotech companies like GTHX that are perceived as riskier investments.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for GTHX including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss G1 Therapeutics, Inc. (GTHX) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for GTHX.

Make a Prediction

Set your price target for G1 Therapeutics, Inc. (GTHX), choose a timeframe, and track your prediction accuracy.

Current price: $7.16

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GTHX.

Price Targets

Wall Street price target analysis for GTHX.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates GTHX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does G1 Therapeutics, Inc. do?

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer patients. The company's lead product, COSELA, is approved to decrease chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer. In addition to COSELA, G1 Therapeutics has a pipeline of clinical-stage programs, including trilaciclib, lerociclib, and rintodestrant, targeting various cancer indications. The company aims to improve patient outcomes and quality of life by developing innovative therapies that address unmet needs in cancer treatment.

Is GTHX stock a good buy?

GTHX stock presents a speculative investment opportunity with significant potential upside, balanced by considerable risks. The company's approved product, COSELA, provides a revenue stream, and its pipeline of clinical-stage programs offers potential for future growth. However, the negative profit margin (-58.1%) and reliance on successful clinical trial outcomes pose challenges. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in GTHX, weighing the potential rewards against the inherent risks in the biotechnology industry. The $0.38B market cap may undervalue the company if pipeline drugs are approved.

What are the main risks for GTHX?

The main risks for G1 Therapeutics include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, and pricing pressures. Clinical trial failures could significantly impact the company's pipeline and future growth prospects. Regulatory delays or non-approval of pipeline products could also hinder commercialization efforts. Competition from other cancer therapies and pricing pressures could limit the market potential for COSELA and future products. Additionally, the company's reliance on strategic partners for successful commercialization poses a risk if these partnerships are not successful.

Is GTHX a good stock to buy?

Whether GTHX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the GTHX MoonshotScore?

The MoonshotScore for GTHX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is GTHX data updated?

GTHX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to GTHX is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for GTHX?

Growth catalysts for G1 Therapeutics, Inc. (GTHX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes G1 Therapeutics, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are GTHX's main competitors?

G1 Therapeutics, Inc. (GTHX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether GTHX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about GTHX?

Wall Street analyst coverage for GTHX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is GTHX's market cap?

Market capitalization (market cap) for GTHX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows GTHX's current market cap alongside enterprise value and other valuation metrics.

How has GTHX stock performed recently?

GTHX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing GTHX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in GTHX?

Key risk categories for GTHX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures GTHX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling GTHX?

Insider trading activity for GTHX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is GTHX a good stock for beginners?

G1 Therapeutics, Inc. (GTHX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is GTHX for first-time investors?

Every stock carries risk, including G1 Therapeutics, Inc. (GTHX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like GTHX.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Stock data pending update may impact financial metrics.
  • Clinical trial outcomes are inherently uncertain.
Data Sources
profilefundamentalsexistingCopy